Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP, Research & Development | February 02, 2012 | February 06, 2012 |
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director · See remarks | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe V-P & Pres, MRL | May 01, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date February 02, 2012 · Filed February 06, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 261,031 |
Reported balance
After 2012-02-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2012-02-02 · Exercise / conversion · Acquired 75,000 · Balance 261,031 |
| Common StockSEC Table I · non-derivative | Direct | 186,031 |
Reported balance
After 2012-02-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2012-02-02 · Sale · Disposed 75,000 · Balance 186,031 F1: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.61 · Expires 2012-03-15 | Direct | 0 |
Reported balance
After 2012-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-02-02 · Exercise / conversion · Disposed 75,000 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 268,176 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 268,176 · Balance 268,176 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date May 01, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.67 · Expires 2030-04-30 | Direct | 151,029 |
Reported balance
After 2020-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-01 · Grant · Acquired 151,029 · Balance 151,029 F2: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. |
| Common StockSEC Table I · non-derivative | Direct | 215,059.579 |
Reported balance
Holding disclosure · report date 2020-05-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 215,059.579 F1: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2032-05-17 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 24,222 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.24 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 46,238 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.40 | $82,396.20 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 17 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.39 | $82,394.00 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 16 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 3,000 | $82.39 | $247,170.00 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 15 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.36 | $82,360.50 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 14 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.33 | $82,331.10 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 13 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.30 | $82,299.80 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 12 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.27 | $82,273.10 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 11 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.26 | $82,264.10 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 10 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,000 | $82.26 | $164,512.20 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 9 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 3,000 | $82.25 | $246,750.00 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 8 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.24 | $82,242.10 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 7 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 7,000 | $82.24 | $575,680.00 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 6 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.23 | $82,229.90 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 5 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.20 | $82,199.00 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 4 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.20 | $82,197.90 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.19 | $82,191.90 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,281 Read SEC document |
| November 17, 2005 Filed Nov 21, 2005 17:37 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $82.19 | $82,190.10 |
DisclosureSEC source: 0001181431-05-062442 · rrd97752.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,281 Read SEC document |
| August 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 200 | $80.90 | $16,180.00 |
DisclosureSEC source: 0001181431-05-042668 · rrd87287.xml · nonDerivative · entry 14 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,281 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $38.36 | $0.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · derivative · entry 31 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,391 Underlying: Common Stock · 40,000 shares Expires 2009-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 700 | $81.15 | $56,805.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 30 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,781 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 800 | $81.14 | $64,912.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 29 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,481 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 600 | $81.13 | $48,678.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 28 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,281 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 600 | $81.12 | $48,672.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 27 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,881 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $81.11 | $81,110.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 26 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,481 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,100 | $81.10 | $89,210.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 25 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,481 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 500 | $81.09 | $40,545.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 24 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,581 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 800 | $81.08 | $64,864.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 23 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,081 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $81.07 | $24,321.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 22 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,881 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $81.06 | $8,106.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 21 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,181 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $81.05 | $8,105.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 20 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,281 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,000 | $81.04 | $81,040.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 19 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,381 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,200 | $81.03 | $97,236.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 18 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,381 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,400 | $81.02 | $113,428.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 17 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,581 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,800 | $81.01 | $145,818.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 16 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,981 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 3,300 | $81.00 | $267,300.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 15 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,781 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,500 | $80.99 | $202,475.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 14 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,081 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,100 | $80.98 | $170,058.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 13 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,581 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,275 | $80.97 | $184,206.75 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 12 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,681 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,525 | $80.96 | $123,464.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 11 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,956 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,600 | $80.95 | $129,520.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 10 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,481 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $80.94 | $24,282.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 9 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,081 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,300 | $80.93 | $105,209.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 8 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,381 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 3,300 | $80.92 | $267,036.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 7 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,681 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,500 | $80.91 | $121,365.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 6 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,981 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 200 | $80.89 | $16,178.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 5 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,481 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $80.88 | $24,264.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 4 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,681 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 200 | $80.87 | $16,174.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,981 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $80.86 | $8,086.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,181 Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 40,000 | $38.36 | $1,534,400.00 |
DisclosureSEC source: 0001181431-05-042666 · rrd87277.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2005 Filed Jul 28, 2005 21:01 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $81.34 | $8,134.00 |
DisclosureSEC source: 0001181431-05-042668 · rrd87287.xml · nonDerivative · entry 13 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,481 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.